Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Similar presentations


Presentation on theme: "Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard."— Presentation transcript:

1 Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard Medical School Surgeon The Newton-Wellesley Hospital Breast Center Is Post-Lumpectomy Radiation Necessary in Older Patients?

2 1.9 cm, ER+, clinical N0 Cancer Lumpectomy Plus Radiation/Boost Tamoxifen Sentinel Node Chemotherapy BRCA testing

3 1.9 cm, ER+, clinical N0 Cancer Lumpectomy Plus Radiation/Boost Tamoxifen Sentinel Node Chemotherapy BRCA testing Lumpectomy Plus Radiation/Boost Tamoxifen/AI Sentinel Node Chemotherapy BRCA testing

4 CALGB 9343 Comparison of Lumpectomy Plus Tamoxifen With and Without Irradiation in Women 70 or Older with Clinical Stage I, ER+ Breast Carcinoma Kevin S. Hughes, Lauren A. Schnaper, Constance Cirrincione, Donald Berry, Beryl McCormick, Hyman B. Muss, Clifford Hudis, Eric Winer, Barbara L. Smith Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group

5 CALGB 9343 ELIGIBILITY Age  70 ELIGIBILITY Age  70Clinically Node Negative Lumpectomy, Negative Margin Tumor size  2 cm Node Negative Lumpectomy, Negative Margin Tumor size  2 cm ER Positive or Indeterminate STRATIFICATION Age < 75  75 Axillary Dissection Yes No RadiationTamoxifen Tamoxifen RANDOMIZERANDOMIZERANDOMIZERANDOMIZE

6 CALGB 9343 Opened July 15, 1994 Closed February 26, patients –Eligible 631 –Ineligible 5 –Canceled/Never treated 11 Median follow-up 12 years

7 Patient characteristics RT+Tam Tam Total treated Age > (56%)172 (54%) ER Positive308 (97%)310 (97%) Size < 2cm295 (93%)296 (93%) No Ax dissection 200 (63%)203 (64%)

8 IBTR (Ipsilateral Breast Tumor Recurrence) 91% 98%

9 Ipsilateral cancer risk 40 and under RT 70 above no RT LCIS

10 Radiation decreases local recurrence by ~7% Does it do anything else?

11

12 No RT Mastectomy Lumpectomy IBTR 27 RT IBTR

13

14

15

16

17 Actuarial survival for given ages at entry D. Berry 8/28/11

18 Ultimate Outcome

19 Breast Recurrence Less Ultimate Mastectomy Same Second primary cancer Same Distant metastasis Same Death Same Death Other CausesSame Death from breast cancerSame 22 women With modern margins and AI’s, RT will likely have even less benefit CONCLUSION: In older women, the benefits of radiation after lumpectomy are small

20


Download ppt "Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard."

Similar presentations


Ads by Google